Skip to main content
Top
Published in: BMC Gastroenterology 1/2024

Open Access 01-12-2024 | Hepatocellular Carcinoma | Research

Prediction of survival and analysis of prognostic factors for patients with AFP negative hepatocellular carcinoma: a population-based study

Authors: Chengyu Liu, Zikang Li, Zhilei Zhang, Jinlong Li, Congxi Xu, Yuming Jia, Chong Zhang, Wuhan Yang, Wenchuan Wang, Xiaojuan Wang, Kuopeng Liang, Li Peng, Jitao Wang

Published in: BMC Gastroenterology | Issue 1/2024

Login to get access

Abstract

Purpose

Hepatocellular carcinoma (HCC) has a poor prognosis, and alpha-fetoprotein (AFP) is widely used to evaluate HCC. However, the proportion of AFP-negative individuals cannot be disregarded. This study aimed to establish a nomogram of risk factors affecting the prognosis of patients with AFP-negative HCC and to evaluate its diagnostic efficiency.

Patients and methods

Data from patients with AFP-negative initial diagnosis of HCC (ANHC) between 2004 and 2015 were collected from the Surveillance, Epidemiology, and End Results database for model establishment and validation. We randomly divided overall cohort into the training or validation cohort (7:3). Univariate and multivariate Cox regression analysis were used to identify the risk factors. We constructed nomograms with overall survival (OS) and cancer-specific survival (CSS) as clinical endpoint events and constructed survival analysis by using Kaplan-Meier curve. Also, we conducted internal validation with Receiver Operating Characteristic (ROC) analysis and Decision curve analysis (DCA) to validate the clinical value of the model.

Results

This study included 1811 patients (1409 men; 64.7% were Caucasian; the average age was 64 years; 60.7% were married). In the multivariate analysis, the independent risk factors affecting prognosis were age, ethnicity, year of diagnosis, tumor size, tumor grade, surgery, chemotherapy, and radiotherapy. The nomogram-based model related C-indexes were 0.762 (95% confidence interval (CI): 0.752–0.772) and 0.752 (95% CI: 0.740–0.769) for predicting OS, and 0.785 (95% CI: 0.774–0.795) and 0.779 (95% CI: 0.762–0.795) for predicting CSS. The nomogram model showed that the predicted death was consistent with the actual value. The ROC analysis and DCA showed that the nomogram had good clinical value compared with TNM staging.

Conclusion

The age(HR:1.012, 95% CI: 1.006–1.018, P-value < 0.001), ethnicity(African-American: HR:0.946, 95% CI: 0.783–1.212, P-value: 0.66; Others: HR:0.737, 95% CI: 0.613–0.887, P-value: 0.001), tumor diameter(HR:1.006, 95% CI: 1.004–1.008, P-value < 0.001), year of diagnosis (HR:0.852, 95% CI: 0.729–0.997, P-value: 0.046), tumor grade(Grade 2: HR:1.124, 95% CI: 0.953–1.326, P-value: 0.164; Grade 3: HR:1.984, 95% CI: 1.574–2.501, P-value < 0.001; Grade 4: HR:2.119, 95% CI: 1.115–4.027, P-value: 0.022), surgery(Liver Resection: HR:0.193, 95% CI: 0.160–0.234, P-value < 0.001; Liver Transplant: HR:0.102, 95% CI: 0.072–0.145, P-value < 0.001), chemotherapy(HR:0.561, 95% CI: 0.471–0.668, P-value < 0.001), and radiotherapy(HR:0.641, 95% CI: 0.463–0.887, P-value:0.007) were independent prognostic factors for patients with ANHC. We developed a nomogram model for predicting the OS and CSS of patients with ANHC, with a good predictive performance.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. PubMed PMID: 33538338. Epub 2021/02/05.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. PubMed PMID: 33538338. Epub 2021/02/05.CrossRefPubMed
2.
go back to reference Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395(1–2):19–26. PubMed PMID: 18538135. Epub 2008/06/10.CrossRefPubMed Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395(1–2):19–26. PubMed PMID: 18538135. Epub 2008/06/10.CrossRefPubMed
3.
go back to reference Qian X, Liu Y, Wu F, Zhang S, Gong J, Nan Y et al. The performance of serum alpha-fetoprotein for detecting early-stage Hepatocellular Carcinoma is influenced by antiviral therapy and serum aspartate aminotransferase: a study in a large cohort of Hepatitis B Virus-infected patients. Viruses. 2022;14(8). PubMed PMID: 36016291. Pubmed Central PMCID: PMC9416230. Epub 2022/08/27. Qian X, Liu Y, Wu F, Zhang S, Gong J, Nan Y et al. The performance of serum alpha-fetoprotein for detecting early-stage Hepatocellular Carcinoma is influenced by antiviral therapy and serum aspartate aminotransferase: a study in a large cohort of Hepatitis B Virus-infected patients. Viruses. 2022;14(8). PubMed PMID: 36016291. Pubmed Central PMCID: PMC9416230. Epub 2022/08/27.
4.
go back to reference Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–8. PubMed PMID: 19362088. Pubmed Central PMCID: PMC2704256. Epub 2009/04/14.CrossRefPubMed Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–8. PubMed PMID: 19362088. Pubmed Central PMCID: PMC2704256. Epub 2009/04/14.CrossRefPubMed
5.
go back to reference Terentiev AA, Moldogazieva NT. Alpha-fetoprotein: a renaissance. Tumour Biol. 2013;34(4):2075–91. PubMed PMID: 23765762. Epub 2013/06/15.CrossRefPubMed Terentiev AA, Moldogazieva NT. Alpha-fetoprotein: a renaissance. Tumour Biol. 2013;34(4):2075–91. PubMed PMID: 23765762. Epub 2013/06/15.CrossRefPubMed
6.
go back to reference Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34(4):570–5. PubMed PMID: 11394657. Epub 2001/06/08.CrossRefPubMed Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34(4):570–5. PubMed PMID: 11394657. Epub 2001/06/08.CrossRefPubMed
7.
go back to reference Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with Hepatocellular Carcinoma. Gastroenterology. 2016;150(4):835–53. PubMed PMID: 26795574. Epub 2016/01/23.CrossRefPubMed Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with Hepatocellular Carcinoma. Gastroenterology. 2016;150(4):835–53. PubMed PMID: 26795574. Epub 2016/01/23.CrossRefPubMed
8.
go back to reference Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870. PubMed PMID: 28993684. Pubmed Central PMCID: PMC5634482. Epub 2017/10/11.ADSCrossRefPubMedPubMedCentral Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870. PubMed PMID: 28993684. Pubmed Central PMCID: PMC5634482. Epub 2017/10/11.ADSCrossRefPubMedPubMedCentral
9.
go back to reference Lin K, Huang Q, Zeng J, Ding Z, Wang L, Chen Z, et al. Clinical significance of alpha-fetoprotein in alpha-fetoprotein negative Hepatocellular Carcinoma underwent curative resection. Dig Dis Sci. 2021;66(12):4545–56. PubMed PMID: 33723698. Pubmed Central PMCID: PMC8589766. Epub 2021/03/17.CrossRefPubMedPubMedCentral Lin K, Huang Q, Zeng J, Ding Z, Wang L, Chen Z, et al. Clinical significance of alpha-fetoprotein in alpha-fetoprotein negative Hepatocellular Carcinoma underwent curative resection. Dig Dis Sci. 2021;66(12):4545–56. PubMed PMID: 33723698. Pubmed Central PMCID: PMC8589766. Epub 2021/03/17.CrossRefPubMedPubMedCentral
10.
11.
go back to reference Hu X, Chen R, Wei Q, Xu X. The Landscape of Alpha Fetoprotein in Hepatocellular Carcinoma: where are we? Int J Biol Sci. 2022;18(2):536–51. PubMed PMID: 35002508. Pubmed Central PMCID: PMC8741863. Epub 2022/01/11.CrossRefPubMedPubMedCentral Hu X, Chen R, Wei Q, Xu X. The Landscape of Alpha Fetoprotein in Hepatocellular Carcinoma: where are we? Int J Biol Sci. 2022;18(2):536–51. PubMed PMID: 35002508. Pubmed Central PMCID: PMC8741863. Epub 2022/01/11.CrossRefPubMedPubMedCentral
12.
go back to reference Zhou JM, Wang T, Zhang KH. AFP-L3 for the diagnosis of early hepatocellular carcinoma: a meta-analysis. Med (Baltim). 2021;100(43):e27673. PubMed PMID: 34713864. Pubmed Central PMCID: PMC8556013. Epub 2021/10/30.CrossRef Zhou JM, Wang T, Zhang KH. AFP-L3 for the diagnosis of early hepatocellular carcinoma: a meta-analysis. Med (Baltim). 2021;100(43):e27673. PubMed PMID: 34713864. Pubmed Central PMCID: PMC8556013. Epub 2021/10/30.CrossRef
13.
go back to reference Zhou D, Liu X, Wang X, Yan F, Wang P, Yan H, et al. A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy. BMC Cancer. 2021;21(1):246. PubMed PMID: 33685417. Pubmed Central PMCID: PMC7938545. Epub 2021/03/10.CrossRefPubMedPubMedCentral Zhou D, Liu X, Wang X, Yan F, Wang P, Yan H, et al. A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy. BMC Cancer. 2021;21(1):246. PubMed PMID: 33685417. Pubmed Central PMCID: PMC7938545. Epub 2021/03/10.CrossRefPubMedPubMedCentral
14.
go back to reference Li W, Han L, Xiao B, Li X, Ye Z. A predictive nomogram of early recurrence for patients with AFP-Negative Hepatocellular Carcinoma underwent curative resection. Diagnostics (Basel). 2022;12(5). PubMed PMID: 35626229. Pubmed Central PMCID: PMC9140180. Epub 2022/05/29. Li W, Han L, Xiao B, Li X, Ye Z. A predictive nomogram of early recurrence for patients with AFP-Negative Hepatocellular Carcinoma underwent curative resection. Diagnostics (Basel). 2022;12(5). PubMed PMID: 35626229. Pubmed Central PMCID: PMC9140180. Epub 2022/05/29.
15.
go back to reference Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93. PubMed PMID: 34801630. Pubmed Central PMCID: PMC8866082. Epub 2021/11/22.CrossRefPubMed Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93. PubMed PMID: 34801630. Pubmed Central PMCID: PMC8866082. Epub 2021/11/22.CrossRefPubMed
16.
go back to reference Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003;139(1):46–50. PubMed PMID: 12834318. Epub 2003/07/02.CrossRefPubMed Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003;139(1):46–50. PubMed PMID: 12834318. Epub 2003/07/02.CrossRefPubMed
17.
go back to reference Feng H, Li B, Li Z, Wei Q, Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer. 2021;21(1):401. PubMed PMID: 33849479. Pubmed Central PMCID: PMC8045263. Epub 2021/04/15.CrossRefPubMedPubMedCentral Feng H, Li B, Li Z, Wei Q, Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer. 2021;21(1):401. PubMed PMID: 33849479. Pubmed Central PMCID: PMC8045263. Epub 2021/04/15.CrossRefPubMedPubMedCentral
18.
go back to reference Wang M, Devarajan K, Singal AG, Marrero JA, Dai J, Feng Z, et al. The Doylestown Algorithm: a test to improve the performance of AFP in the detection of Hepatocellular Carcinoma. Cancer Prev Res (Phila). 2016;9(2):172–9. PubMed PMID: 26712941. Pubmed Central PMCID: PMC4740237. Epub 2015/12/30.CrossRefPubMed Wang M, Devarajan K, Singal AG, Marrero JA, Dai J, Feng Z, et al. The Doylestown Algorithm: a test to improve the performance of AFP in the detection of Hepatocellular Carcinoma. Cancer Prev Res (Phila). 2016;9(2):172–9. PubMed PMID: 26712941. Pubmed Central PMCID: PMC4740237. Epub 2015/12/30.CrossRefPubMed
19.
go back to reference Wang T, Zhang KH. New blood biomarkers for the diagnosis of AFP-Negative Hepatocellular Carcinoma. Front Oncol. 2020;10:1316. PubMed PMID: 32923383. Pubmed Central PMCID: PMC7456927. Epub 2020/09/15.CrossRefPubMedPubMedCentral Wang T, Zhang KH. New blood biomarkers for the diagnosis of AFP-Negative Hepatocellular Carcinoma. Front Oncol. 2020;10:1316. PubMed PMID: 32923383. Pubmed Central PMCID: PMC7456927. Epub 2020/09/15.CrossRefPubMedPubMedCentral
20.
go back to reference Zhang H, Du X, Dong H, Xu W, Zhou P, Liu S, et al. Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database. BMC Gastroenterol. 2022;22(1):348. PubMed PMID: 35854221. Pubmed Central PMCID: PMC9297630. Epub 2022/07/20.CrossRefPubMedPubMedCentral Zhang H, Du X, Dong H, Xu W, Zhou P, Liu S, et al. Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database. BMC Gastroenterol. 2022;22(1):348. PubMed PMID: 35854221. Pubmed Central PMCID: PMC9297630. Epub 2022/07/20.CrossRefPubMedPubMedCentral
21.
go back to reference Xie J, Zheng C, Xie J, Wang F, Liu D, Zeng R, et al. No significant relationship exists between tumor size and prognosis in distant metastatic hepatocellular carcinoma: a propensity score matching analysis based on SEER database. BMC Gastroenterol. 2022;22(1):274. PubMed PMID: 35655184. Pubmed Central PMCID: PMC9161599. Epub 2022/06/03.CrossRefPubMedPubMedCentral Xie J, Zheng C, Xie J, Wang F, Liu D, Zeng R, et al. No significant relationship exists between tumor size and prognosis in distant metastatic hepatocellular carcinoma: a propensity score matching analysis based on SEER database. BMC Gastroenterol. 2022;22(1):274. PubMed PMID: 35655184. Pubmed Central PMCID: PMC9161599. Epub 2022/06/03.CrossRefPubMedPubMedCentral
22.
go back to reference Liu M, Xu M, Tang T. Association between chemotherapy and prognostic factors of survival in hepatocellular carcinoma: a SEER population-based cohort study. Sci Rep. 2021;11(1):23754. PubMed PMID: 34887446. Pubmed Central PMCID: PMC8660869. Epub 2021/12/11.ADSCrossRefPubMedPubMedCentral Liu M, Xu M, Tang T. Association between chemotherapy and prognostic factors of survival in hepatocellular carcinoma: a SEER population-based cohort study. Sci Rep. 2021;11(1):23754. PubMed PMID: 34887446. Pubmed Central PMCID: PMC8660869. Epub 2021/12/11.ADSCrossRefPubMedPubMedCentral
23.
go back to reference Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. PubMed PMID: 33479224. Epub 2021/01/23.CrossRefPubMed Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. PubMed PMID: 33479224. Epub 2021/01/23.CrossRefPubMed
24.
go back to reference Nephew LD, Gupta D, Carter A, Desai AP, Ghabril M, Patidar KR, et al. Social determinants of health impact mortality from HCC and Cholangiocarcinoma: a population-based cohort study. Hepatol Commun. 2023;7(3):e0058. PubMed PMID: 36757397. Epub 2023/02/10.CrossRefPubMedPubMedCentral Nephew LD, Gupta D, Carter A, Desai AP, Ghabril M, Patidar KR, et al. Social determinants of health impact mortality from HCC and Cholangiocarcinoma: a population-based cohort study. Hepatol Commun. 2023;7(3):e0058. PubMed PMID: 36757397. Epub 2023/02/10.CrossRefPubMedPubMedCentral
25.
go back to reference Lu W, Zheng F, Li Z, Zhou R, Deng L, Xiao W, et al. Association between Environmental and Socioeconomic Risk Factors and Hepatocellular Carcinoma: a Meta-analysis. Front Public Health. 2022;10:741490. PubMed PMID: 35252078. Pubmed Central PMCID: PMC8893961. Epub 2022/03/08.CrossRefPubMedPubMedCentral Lu W, Zheng F, Li Z, Zhou R, Deng L, Xiao W, et al. Association between Environmental and Socioeconomic Risk Factors and Hepatocellular Carcinoma: a Meta-analysis. Front Public Health. 2022;10:741490. PubMed PMID: 35252078. Pubmed Central PMCID: PMC8893961. Epub 2022/03/08.CrossRefPubMedPubMedCentral
26.
go back to reference Chen F, Wu Y, Xu H, Song T, Yan S. Impact of marital status on overall survival in patients with early-stage hepatocellular carcinoma. Sci Rep. 2022;12(1):19923. PubMed PMID: 36402820. Pubmed Central PMCID: PMC9675859. Epub 2022/11/20.ADSCrossRefPubMedPubMedCentral Chen F, Wu Y, Xu H, Song T, Yan S. Impact of marital status on overall survival in patients with early-stage hepatocellular carcinoma. Sci Rep. 2022;12(1):19923. PubMed PMID: 36402820. Pubmed Central PMCID: PMC9675859. Epub 2022/11/20.ADSCrossRefPubMedPubMedCentral
27.
go back to reference Zhang L, Chen J, Ning D, Liu Q, Wang C, Zhang Z, et al. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21. J Exp Clin Cancer Res. 2019;38(1):101. PubMed PMID: 30808376. Pubmed Central PMCID: PMC6390379. Epub 2019/02/28.CrossRefPubMedPubMedCentral Zhang L, Chen J, Ning D, Liu Q, Wang C, Zhang Z, et al. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21. J Exp Clin Cancer Res. 2019;38(1):101. PubMed PMID: 30808376. Pubmed Central PMCID: PMC6390379. Epub 2019/02/28.CrossRefPubMedPubMedCentral
28.
go back to reference Wang X, Mao M, He Z, Zhang L, Li H, Lin J, et al. Development and validation of a Prognostic Nomogram in AFP-negative hepatocellular carcinoma. Int J Biol Sci. 2019;15(1):221–8. PubMed PMID: 30662361. Pubmed Central PMCID: PMC6329916. Epub 2019/01/22.CrossRefPubMedPubMedCentral Wang X, Mao M, He Z, Zhang L, Li H, Lin J, et al. Development and validation of a Prognostic Nomogram in AFP-negative hepatocellular carcinoma. Int J Biol Sci. 2019;15(1):221–8. PubMed PMID: 30662361. Pubmed Central PMCID: PMC6329916. Epub 2019/01/22.CrossRefPubMedPubMedCentral
29.
go back to reference Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13(2):125–37. PubMed PMID: 30600478. Epub 2019/01/03.CrossRefPubMed Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13(2):125–37. PubMed PMID: 30600478. Epub 2019/01/03.CrossRefPubMed
30.
go back to reference Mao S, Yu X, Shan Y, Fan R, Wu S, Lu C. Albumin-Bilirubin (ALBI) and Monocyte to lymphocyte ratio (MLR)-Based Nomogram Model to Predict Tumor recurrence of AFP-Negative Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021;8:1355–65. PubMed PMID: 34805014. Pubmed Central PMCID: PMC8594894. Epub 2021/11/23.CrossRefPubMedPubMedCentral Mao S, Yu X, Shan Y, Fan R, Wu S, Lu C. Albumin-Bilirubin (ALBI) and Monocyte to lymphocyte ratio (MLR)-Based Nomogram Model to Predict Tumor recurrence of AFP-Negative Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021;8:1355–65. PubMed PMID: 34805014. Pubmed Central PMCID: PMC8594894. Epub 2021/11/23.CrossRefPubMedPubMedCentral
31.
go back to reference Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2017;6(6):387–96. PubMed PMID: 29312973. Pubmed Central PMCID: PMC5756765. Epub 2018/01/10.CrossRefPubMedPubMedCentral Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2017;6(6):387–96. PubMed PMID: 29312973. Pubmed Central PMCID: PMC5756765. Epub 2018/01/10.CrossRefPubMedPubMedCentral
32.
go back to reference Garuti F, Neri A, Avanzato F, Gramenzi A, Rampoldi D, Rucci P, et al. The changing scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 2020;41(3):585–97.CrossRefPubMed Garuti F, Neri A, Avanzato F, Gramenzi A, Rampoldi D, Rucci P, et al. The changing scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 2020;41(3):585–97.CrossRefPubMed
33.
go back to reference Ielasi L, Tovoli F, Tonnini M, Stefanini B, Tortora R, Magini G et al. Prognostic impact of metastatic site in patients receiving first-line Sorafenib Therapy for Advanced Hepatocellular Carcinoma. Cancers (Basel). 2023;15(5). PubMed PMID: 36900314. Pubmed Central PMCID: PMC10000514. Epub 2023/03/12. Ielasi L, Tovoli F, Tonnini M, Stefanini B, Tortora R, Magini G et al. Prognostic impact of metastatic site in patients receiving first-line Sorafenib Therapy for Advanced Hepatocellular Carcinoma. Cancers (Basel). 2023;15(5). PubMed PMID: 36900314. Pubmed Central PMCID: PMC10000514. Epub 2023/03/12.
34.
go back to reference Zhang S, Yuan L, Danilova L, Mo G, Zhu Q, Deshpande A, et al. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence. Genome Med. 2023;15(1):72. PubMed PMID: 37723590. Pubmed Central PMCID: PMC10506285. Epub 2023/09/19.CrossRefPubMedPubMedCentral Zhang S, Yuan L, Danilova L, Mo G, Zhu Q, Deshpande A, et al. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence. Genome Med. 2023;15(1):72. PubMed PMID: 37723590. Pubmed Central PMCID: PMC10506285. Epub 2023/09/19.CrossRefPubMedPubMedCentral
35.
go back to reference Wu XK, Yang LF, Chen YF, Chen ZW, Lu H, Shen XY, et al. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study. EClinicalMedicine. 2024;67:102367. PubMed PMID: 38169778. Pubmed Central PMCID: PMC10758712. Epub 2024/01/04.CrossRefPubMed Wu XK, Yang LF, Chen YF, Chen ZW, Lu H, Shen XY, et al. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study. EClinicalMedicine. 2024;67:102367. PubMed PMID: 38169778. Pubmed Central PMCID: PMC10758712. Epub 2024/01/04.CrossRefPubMed
36.
go back to reference Wang X, Cao W, Qiu Y, Ji H, Yuan J, Wu W et al. Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery. Front Oncol. 2023;13:1174999. PubMed PMID: 38162488. Pubmed Central PMCID: PMC10755294. Epub 2024/01/02. Wang X, Cao W, Qiu Y, Ji H, Yuan J, Wu W et al. Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery. Front Oncol. 2023;13:1174999. PubMed PMID: 38162488. Pubmed Central PMCID: PMC10755294. Epub 2024/01/02.
37.
go back to reference Stefanini B, Ielasi L, Chen R, Abbati C, Tonnini M, Tovoli F, et al. TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2023;23(3):279–91.CrossRefPubMed Stefanini B, Ielasi L, Chen R, Abbati C, Tonnini M, Tovoli F, et al. TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2023;23(3):279–91.CrossRefPubMed
38.
go back to reference D’Avola D, Granito A, Torre-Aláez Mdl, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol. 2022;76(5):1185–98.CrossRefPubMed D’Avola D, Granito A, Torre-Aláez Mdl, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol. 2022;76(5):1185–98.CrossRefPubMed
39.
go back to reference Ielasi L, Stefanini B, Conti F, Tonnini M, Tortora R, Magini G, et al. Comparative Analysis of Subclassification Systems in patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver classification B) receiving systemic therapy. Curr Oncol. 2024;31(1):547–57.CrossRefPubMedPubMedCentral Ielasi L, Stefanini B, Conti F, Tonnini M, Tortora R, Magini G, et al. Comparative Analysis of Subclassification Systems in patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver classification B) receiving systemic therapy. Curr Oncol. 2024;31(1):547–57.CrossRefPubMedPubMedCentral
Metadata
Title
Prediction of survival and analysis of prognostic factors for patients with AFP negative hepatocellular carcinoma: a population-based study
Authors
Chengyu Liu
Zikang Li
Zhilei Zhang
Jinlong Li
Congxi Xu
Yuming Jia
Chong Zhang
Wuhan Yang
Wenchuan Wang
Xiaojuan Wang
Kuopeng Liang
Li Peng
Jitao Wang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2024
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-024-03185-z

Other articles of this Issue 1/2024

BMC Gastroenterology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.